文献速递前列腺癌

前列腺放疗对转移性去势敏感性前列腺癌生存结局的影响:随机III期临床试验的荟萃分析

Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials.
PubMed 文献 · Eur Urol Oncol · 2025-05-30

该荟萃分析纳入HORRAD、STAMPEDE和PEACE-1三项III期试验共3665例转移性去势敏感性前列腺癌患者,评估在标准治疗基础上加用前列腺放疗对影像学无进展生存(rPFS)和总生存(OS)的影响。结果显示,总体人群中放疗未改善rPFS或OS;但在低瘤负荷患者中,放疗联合标准治疗和阿比特龙酯(AA)显著改善rPFS(HR=0.65,95%CI:0.45-0.93;p=0.02),但未观察到OS获益。

要点

  • 总体mCSPC人群中,前列腺放疗未改善rPFS或OS。
  • 低瘤负荷患者中,放疗联合SOC和AA显著改善rPFS。
  • 低瘤负荷患者中未观察到OS获益。

核心结论

  • 前列腺放疗在总体mCSPC人群中未改善rPFS或OS。
  • 低瘤负荷患者中,放疗联合SOC和AA显著改善rPFS但无OS获益。

研究设计与样本

  • 针对HORRAD、STAMPEDE和PEACE-1三项III期试验的靶向综述与荟萃分析,共纳入3665例患者。
  • 采用随机效应模型(Review Manager v5.3)分析rPFS和OS,以风险比(HR)及95%置信区间(CI)表示。
  • 亚组分析聚焦于按CHAARTED标准定义的低瘤负荷疾病,异质性通过I2评估,显著性设定为p<0.05。

主要发现

  • 总体mCSPC人群中,放疗联合SOC未改善rPFS或OS。
  • 低瘤负荷疾病中,放疗联合SOC和AA显著改善rPFS(HR=0.65,95%CI:0.45-0.93;p=0.02),但无OS获益。

关键数值与推荐

  • 低瘤负荷疾病按CHAARTED标准定义。
  • rPFS改善的HR=0.65,95%CI:0.45-0.93,p=0.02。

临床怎么用

  • 前列腺放疗不应在总体mCSPC人群中常规用于改善rPFS或OS。
  • 对于低瘤负荷mCSPC患者,可考虑在SOC和AA基础上加用前列腺放疗以改善rPFS。

局限性

  • 基于合并数据,存在患者异质性。
  • 治疗方案和随访存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Despite advancements in systemic therapy for metastatic castration-sensitive prostate cancer (mCSPC), the survival benefits of radiotherapy (RT) remain uncertain. This meta-analysis evaluates whether addition of RT to the standard of care (SOC) improves radiographic progression-free (rPFS) and overall (OS) survival, with a focus on systemic therapy intensification. METHODS: A targeted review of three phase 3 trials (HORRAD, STAMPEDE, and PEACE-1) was conducted to assess the role of prostate RT in mCSPC. Two reviewers evaluated study quality, and a meta-analysis using a random-effect model (Review Manager v5.3) analyzed rPFS and OS as the primary outcomes (hazard ratio [HR] with 95% confidence interval [CI]). Subgroup analyses focused on low-volume disease as per the CHAARTED criteria, with heterogeneity assessed via I2 and significance set at p < 0.05. KEY FINDINGS AND LIMITATIONS: This meta-analysis of 3665 patients from HORRAD, STAMPEDE, and PEACE-1 found that addition of RT to SOC did not improve rPFS or OS in the overall mCSPC population. However, in low-volume disease, RT with SOC and abiraterone acetate (AA) improved rPFS significantly (HR = 0.65, 95% CI: 0.45-0.93; p = 0.02) without an OS benefit. Limitations include pooled data, patient heterogeneity, and variations in treatments and follow-up. CONCLUSIONS AND CLINICAL IMPLICATIONS: Prostate RT does not improve rPFS or OS in the overall mCSPC population, but offers a significant rPFS benefit in low-volume disease when combined with SOC and AA. Although no OS improvement was observed, the synergy between AA and RT underscores the value of RT for carefully selected patients. Further prospective studies are needed to refine treatment strategies and improve outcomes.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Yazgan SC, Yekedüz E, Sayan M, et al. Impact of Prostate Radiotherapy on Survival Outcomes in Patients with Metastatic Castration-sensitive Prostate Cancer: A Meta-analysis of Randomized Phase 3 Clinical Trials. Eur Urol Oncol. 2025. PMID: 40447512. doi:10.1016/j.euo.2025.05.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。